Abstract: This invention relates to oral care compositions comprising a cannabinoid, and one more source(s) of zinc ions and/or stannous ions. The oral care composition may also comprise one or more stannous source(s). Methods of using and of making these compositions is also disclosed herein.

Abstract: This invention relates to oral care compositions comprising a cannabinoid source, a thickening system, wherein the thickening system comprises xanthan gum and carrageenan, and an orally acceptable carrier. The invention also relates to oral care compositions comprising a cannabinoid source, a surfactant system, wherein the surfactant system comprises an acyl glutamate, a non-silica abrasive (e.g., calcium carbonate or charcoal) and an orally acceptable carrier. Also disclosed are methods of using and of making these compositions.

Abstract: The present disclosure relates to oral care compositions comprising amino acids and a cannabinoid. Methods of making and use are further provided.

Abstract: The invention relates to methods of treatment and screening natural compounds that can be used to further proliferate orally derived stem cells (e.g., periodontal ligament stem cells, dental pulp stem cells, or stem cells from the apical papilla or gingiva-derived mesenchymal stem cells (GMSC)).

Abstract: Disclosed herein are orally acceptable topical analgesic gels comprising a mixture of herbal oils and extracts comprising (a) clove oil and/or eugenol (e.g., clove leaf oil and/or clove bud oil), (b) a cooling agent (e.g., menthol), (c) camphor, (d) an antimicrobial agent, e.g., turmeric and/or curcumin extract (e.g., turmeric, white turmeric (e.g., white curcumin) and (e) licorice; in an orally acceptable gel base, the gel base comprising one or more nonionic surfactants, the formulation providing a sustained release of the mixture of herbal oils and extracts following application to a tooth or gums; together with methods of making and using the same.

Abstract: Described herein are methods for improving or maintaining the barrier integrity of gingival tissue comprising administering an oral care composition comprising a curcurninoid, to the oral cavity of a subject in need thereof.

Abstract: This invention relates to oral care compositions comprising herbal extracts including, e.g., Gymnema sylvestre, Emblica officinalis, Eugenia jambolana, Azadirachta indica, and combinations thereof and zinc salts, e.g., zinc citrate and zinc oxide. Additionally, the invention relates to methods of using and of making these compositions, e.g., method of using the oral care compositions to treat gingivitis in diabetic consumers.

Abstract: Described herein are oral care compositions comprising vitamin D, or a derivative thereof. Methods of making and using these compositions are also described.

Abstract: Described herein are oral care compositions comprising vitamin D, or a derivative thereof; an alkanoic acid of formula R—COOH or an alkali metal salt thereof, wherein R is a C1 to C13 hydrocarbyl group; and an orally acceptable carrier. Methods of making and using same are also described.

Abstract: Described herein are—inter alia—complexes comprising a curcuminoid; and an anionic surfactant. Methods of making and using same are also described.

Abstract: Uses of a compound of any of Formulas I-VI as a cytotoxic inhibitor of undifferentiated cells are disclosed herein, as well as pharmaceutical compositions comprising a compound of any of Formulas I-VI, and methods for identifying a lead candidate for inhibiting undifferentiated cells. Further disclosed are uses of an SCD-1 inhibitor as a cytotoxic inhibitor of undifferentiated cells.

Abstract: Uses of a compound of any of Formulas I-VI as a cytotoxic inhibitor of undifferentiated cells are disclosed herein, as well as pharmaceutical compositions comprising a compound of any of Formulas I-VI, and methods for identifying a lead candidate for inhibiting undifferentiated cells. Further disclosed are uses of an SCD-1 inhibitor as a cytotoxic inhibitor of undifferentiated cells.

Abstract: Uses of a compound of any of Formulas I-VI as a cytotoxic inhibitor of undifferentiated cells are disclosed herein, as well as pharmaceutical compositions comprising a compound of any of Formulas I-VI, and methods for identifying a lead candidate for inhibiting undifferentiated cells. Further disclosed are uses of an SCD-1 inhibitor as a cytotoxic inhibitor of undifferentiated cells.

Abstract: Uses of a compound of any of Formulas I-VI as a cytotoxic inhibitor of undifferentiated cells are disclosed herein, as well as pharmaceutical compositions comprising a compound of any of Formulas I-VI, and methods for identifying a lead candidate for inhibiting undifferentiated cells. Further disclosed are uses of an SCD-1 inhibitor as a cytotoxic inhibitor of undifferentiated cells.